U.S.A.Breakthrough therapy designation approval and its implications for new drugs review in ChinaYUAN Lin, SHAO Ming-li1-6
Comparison of guidances from FDA, EMA and CFDA on the bioequivalence studies of highly variable drugsLI Zi-qiang, HUANG Yu-hong, WANG Bao-he, LIU Chang-xiao7-13
Economic evaluation of ShufengJiedu capsules versus oseltamivir phosphate capsules for adult patients with influenza-like illness李洪超, 管欣, 田磊, 季明昉, 孟晓, 郁柳, 钱焊森, 岳鹏程, 孙长春14-21
Analysis of affecting factors of technical innovation intention of pharmaceutical industryCAO Yang, QIN Chun-mei22-28
Carcinogenicity studies of direct-acting anti-hepatitis C virus drugs: a reviewYU Chun-rong, DA Hong-yuan, WANG Qing-li32-35
Research progress and trends in rheumatoid arthritis therapeutic drugsHU Xiao-min, ZONG Ying, YU Shan-shan, YUAN Bo-jun, LU Guo-cai, WANG Qing-li36-43
Effects of E2HSA on the glycolipid metabolism and β-cell function in aged obese miceLI Cai-na, HOU Shao-cong, SUN Su-juan, LIU Shuai-nan, JIANG Qian, LIU Quan, SHEN Zhu-fang44-50
Progress in research of the mechanism and preclinical evaluation of drug pseudoallergyCHEN Meng, LI Wei, WANG Xue, HUANG Zhi-ying, GENG Xing-chao, LI Bo51-59
Overview of application of nanotechnology in herbal polysaccharides developmentZHU Ning, ZHANG Le-shuai, WANG Fu-jun60-65